Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

2001 • 24,089 citations

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

1998 • 14,996 citations

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction

1998 • 7,057 citations

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

2004 • 6,926 citations

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

2005 • 6,633 citations

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

2004 • 4,752 citations

Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

1993 • 4,132 citations

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

2003 • 3,816 citations

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

2004 • 3,776 citations

Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

2005 • 3,404 citations

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

2005 • 3,163 citations

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

2003 • 2,931 citations

Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>

2001 • 2,473 citations

Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1997 • 1,657 citations

Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations

1999 • 1,457 citations

Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

2002 • 1,311 citations

Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels

1998 • 1,000 citations

Drug Treatment of Lipid Disorders

1999 • 863 citations

Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction

2000 • 754 citations

The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women

2001 • 538 citations

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

2006 • 534 citations

Type 2 Diabetes as a “Coronary Heart Disease Equivalent”

2005 • 435 citations

Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies

2002 • 397 citations

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

2005 • 390 citations

Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose

2003 • 313 citations

Cardiovascular Events in Diabetic and Nondiabetic Adults With or Without History of Myocardial Infarction

2004 • 267 citations

Diabetes and All-Cause and Coronary Heart Disease Mortality Among US Male Physicians

2001 • 224 citations

Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent?

2005 • 221 citations

Lipoprotein Abnormalities in Well-Treated Type II Diabetic Patients

1993 • 47 citations

Cited By (0)

Loading...